Understanding the factors affecting sensing efficiency in SPR biosensing
Acute lymphoblastic leukemia (ALL) is a disease where immature white blood cells originated from the bone marrow become cancerous, inducing proliferation in the blood flow and subsequently to organs in addition to prevent the proper function of other blood cells. One of the main chemotherapeutic agents proven for its efficacy for ALL is the E. coli L-asparaginase (EcAII) as a biological therapeutic agent. The challenge with undergoing such treatment is that the patient can potentially develop silent inactivation of the biological chemotherapeutic agent by generating antibodies to neutralize EcAII and therefore reducing treatment efficiency.
